When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Abandono do hábito de fumar

Última revisión: 26 Nov 2025
Última actualización: 23 Oct 2025

Resumen

Definición

History and exam

Key diagnostic factors

  • número de cigarros por dia
  • tempo até o primeiro cigarro (TTFC)
  • uso de produtos alternativos de administração de tabaco e nicotina
  • história de transtorno relacionado ao uso de substâncias
  • gestação ou amamentação
Full details

Other diagnostic factors

  • história de depressão
  • história de esquizofrenia
  • transtorno convulsivo
  • hipertensão
  • doença cardíaca instável
  • arritmia ventricular
  • asma
  • doença pulmonar obstrutiva crônica (DPOC)
  • distúrbio da articulação temporomandibular ou problema dentário
Full details

Risk factors

  • idade <24 anos
  • condição socioeconômica baixa
  • história de transtorno mental ou transtorno por uso de substâncias
  • história de HIV/AIDS
  • uso de produtos alternativos de administração de tabaco e nicotina
  • genética
Full details

Diagnostic tests

1st tests to order

  • autorrelato da condição de fumante
  • Teste de Fagerström para a dependência de nicotina (Fagerström Test For Nicotine Dependence; FTND)
  • Índice de Intensidade do Tabagismo (Heaviness of Smoking Index; HSI)
Full details

Tests to consider

  • monitoramento do monóxido de carbono (CO)
  • nível de cotinina
Full details

Treatment algorithm

ACUTE

fumantes ativos hospitalizados

ONGOING

fumantes ativos prontos para parar: adultos (não gestantes/lactantes)

fumantes ativos dispostos a parar: gestantes/lactantes ou adolescentes

fumantes ativos não dispostos a parar

Contributors

Authors

Franck F. Rahaghi, MD, MHS, FCCP

Chairman

Pulmonary Department

Director

Pulmonary Education and Rehabilitation

Cleveland Clinic

Weston

FL

Disclosures

FFR is a consultant and speaker for Bayer, United Therapeutics, Janssen-PH, Merck, Boehringer Ingleheim, Takeda, and Talecris. He is involved in industry-sponsored research with Bayer, Janssen-PH, Gossamer Bio, and Bellerophon.

Samuel Gurevich, MD, FCCP

Pulmonary Department

Director

Respiratory Therapy

Cleveland Clinic

Weston

FL

Disclosures

SG declares that he has no competing interests.

Acknowledgements

Dr Franck F. Rahaghi and Dr Samuel Gurevich would like to gratefully acknowledge Dr Felix Hernandez, Dr Jose Gonzalez, and Dr Theodore W. Marcy, previous contributors to this topic.

Disclosures

FH, JG, and TWM declare that they have no competing interests.

Peer reviewers

Jaymin Morjaria, MBBS, FRCP, MD

Consultant Respiratory Physician

Guy’s and St Thomas NHS Foundation Trust

Harefield Hospital

Middlesex

Honorary Senior Lecturer

Brunel University

London

UK

Disclosures

JM has received honoraria for speaking and financial support to attend meetings/advisory boards from Wyeth, Chiesi, Pfizer, MSD, Boehringer Ingelheim, Teva, GSK/Allen & Hanburys, Napp, Almirall, AstraZeneca, Trudell, Cook Medical, Medela AG, Medtronics, and Novartis. He has been an expert witness in a court case relating to the impact of smoking on illness severity, ITU admissions, and mortality from Covid-19 in South Africa in 2020.

Arran Woodhouse, MSc

Senior Tobacco Programme Manager

North Central London Integrated Care Board

London

UK

Declarações

AW has been reimbursed by Johnson & Johnson Ltd Nicorette UK Consulting for chairing the Smoking Cessation National Advisory Panel on 1 November 2022. He worked with NICE on the recent Tobacco Guideline (NG209) as a topic expert and as a specialist committee member for the treating dependence Quality Standards Advisory Committee (QS 207). He was appointed as an Expert Adviser for the NICE Centre for Guidelines in February 2023. Previous member of the British Thoracic Society's Tobacco Specialist Advisory Group.

Créditos aos pareceristas

Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.

Declarações

As afiliações e declarações dos pareceristas referem--se ao momento da revisão.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

United States Public Health Service Office of the Surgeon General; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Smoking cessation: a report of the Surgeon General. 2020 [internet publication].Texto completo  Resumo

Tobacco Use and Dependence Guideline Panel, US Department of Health and Human Services. Treating tobacco use and dependence: 2008 update. Rockville (MD): US Department of Health and Human Services; 2008.Texto completo

National Institute for Health and Care Excellence. Tobacco: preventing uptake, promoting quitting and treating dependence. Feb 2025 [internet publication].Texto completo

US Preventive Services Task Force. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021 Jan 19;325(3):265-79.Texto completo  Resumo

Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2018 Dec 5;72(25):3332-65.Texto completo  Resumo

Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018 May 31;(5):CD000146.Texto completo  Resumo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Abandono do hábito de fumar images
  • Diagnósticos diferenciais

    • Transtorno relacionado ao uso de substâncias
    Mais Diagnósticos diferenciais
  • Diretrizes

    • Tobacco: preventing uptake, promoting quitting and treating dependence
    • NCCN clinical practice guidelines in oncology: smoking cessation
    Mais Diretrizes
  • Folhetos informativos para os pacientes

    Abandono do hábito de fumar

    Mais Folhetos informativos para os pacientes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal